Background
The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM).Methods
Pre-specified patient-level pooled analysis of all available double-blind, randomized, controlled trials, ≥ 12 weeks' duration (19 trials, 9459 subjects) of linaglip...
